Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 22, Number 9—September 2016

Clinical Features of and Risk Factors for Fatal Ebola Virus Disease, Moyamba District, Sierra Leone, December 2014–February 2015

Yngvar Lunde Haaskjold, Håkon Angell Bolkan, Kurt Østhuus Krogh, James Jongopi, Karen Marie Lundeby, Sindre Mellesmo, Pedro San José Garcés, Ola Jøsendal, Åsmund Øpstad, Erling Svensen, Luis Matias Zabala Fuentes, Alfred Sandy Kamara, Melchor Riera, Javier Arranz, David P. Roberts, Paul D. Stamper, Paula Austin, Alfredo J. Moosa, Dennis Marke, Shoaib Hassan, Geir Egil Eide, Åse Berg, and Bjørn BlombergComments to Author 
Author affiliations: Haukeland University Hospital, Bergen, Norway (Y.L. Haaskjold, O. Jøsendal, E. Svensen, G.E. Eide, B. Blomberg); St. Olav Hospital, Trondheim, Norway (H.A. Bolkan, K.Ø. Krogh, S. Mellesmo); Moyamba District Hospital, Moyamba, Sierra Leone (J. Jongopi, A.S. Kamara, A.J. Moosa, D. Marke); Oslo University Hospital, Oslo, Norway (K.M. Lundeby); Médicos del Mundo, Madrid, Spain (P. San José Garcés, L.M. Zabala Fuentes, J. Arranz); Haraldsplass Diaconal Hospital, Bergen (Å. Øpstad); University of Bergen, Bergen (E. Svensen, G.E. Eide, B. Blomberg); Hospital Son Espases, Palma de Mallorca, Spain (M. Riera); Instituto de Investigacion de Palma (IDISPA), Madrid (J. Arranz); MRIGlobal, Rockville, Maryland, USA (D.P. Roberts, P.D. Stamper); Sandia National Laboratories, Albuquerque, New Mexico, USA (P. Austin); FELTP Public Health, Islamabad, Pakistan (S. Hassan); Stavanger University Hospital, Stavanger, Norway (Å. Berg)

Main Article

Table 2

Treatment given to patients with confirmed Ebola virus disease admitted to the treatment center in Moyamba District, Sierra Leone, December 19, 2014–February 17, 2015*

Treatment No. (%) patients
OR (95% CI) p value†
Total, N = 31 Died, N = 18 Survived, N = 13
Intravenous fluids 26 (84) 17 (94) 9 (69) 7.6 (0.90–97.0) 0.096
Antimalarial drugs 29 (94) 17 (94) 12 (92) 1.4 (0.07–28.0) 0.748
Ceftriaxone 23 (74) 14 (78) 9 (69) 1.6 (0.37–6.4) 0.551
Metronidazol 13. (42) 8 (44) 5 (38) 1.3 (0.33–5.8) 0.864
Albendazol 5 (16) 1 (6) 4 (31) 0.1 (0.01–1.1) 0.096
Zinc 29 (94) 17 (94) 12 (92) 1.4 (0.07–28.0) 0.748

*OR, odds ratio.
†p values calculated by the Fisher 2-tailed exact mid-p test.

Main Article

URL Validation failed because the page does not exist (HTTP error 404).

Page created: August 16, 2016
Page updated: August 16, 2016
Page reviewed: August 16, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.